Adefovir/Entecavir — Competitive Intelligence Brief

Adefovir/Entecavir (Adefovir/Entecavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor. Area: Virology/Infectious Disease.

marketed Nucleoside/nucleotide reverse transcriptase inhibitor Hepatitis B virus polymerase (reverse transcriptase) Virology/Infectious Disease Small molecule

Target snapshot

Adefovir/Entecavir (Adefovir/Entecavir) — Bristol-Myers Squibb. Adefovir and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus (HBV) replication by inhibiting viral polymerase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adefovir/Entecavir TARGET	Adefovir/Entecavir	Bristol-Myers Squibb	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor	Hepatitis B virus polymerase (reverse transcriptase)
Entecavir, Adefovir	Entecavir, Adefovir	Nanfang Hospital, Southern Medical University	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor	Hepatitis B virus polymerase (reverse transcriptase)
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
Emtricitabine and Tenofovir	Emtricitabine and Tenofovir	Puerto Rico Community Network for Clinical Research on AIDS	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
FTC-TDF PrEP	FTC-TDF PrEP	University of Washington	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV reverse transcriptase
Telbivudine, Lamivudine, Adefovir ,Enecavir	Telbivudine, Lamivudine, Adefovir ,Enecavir	Shao-quan Zhang	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI)	Hepatitis B virus reverse transcriptase
Atazanavir / Ritonavir + Tenofovir / Emtricitabine	Atazanavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor class)

1. Bristol-Myers Squibb · 1 drug in this class
2. Nanfang Hospital, Southern Medical University · 1 drug in this class
3. Third Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
4. University of Washington · 1 drug in this class